OWL833, an Orally Active Nonpeptide GLP-1 Receptor Agonist, Improves Glucose Tolerance by Increasing Insulin Secretion and Reduces Food Intake of Cynomolgus Monkeys
Sign Up to like & getrecommendations! Published in 2018 at "Diabetes"
DOI: 10.2337/db18-1118-p
Abstract: Activation of glucagon-like peptide-1 receptors (GLP-1R) is a promising approach for the treatment of type 2 diabetes mellitus (T2D), and several peptide analogues of GLP-1 have been successfully developed. Here we identified a new orally… read more here.
Keywords: chugai pharmaceutical; glp; self chugai; pharmaceutical ltd ... See more keywords